Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Non-Current Assets for 12 consecutive years, with $187.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 5.71% to $187.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $765.1 million through Dec 2025, down 5.11% year-over-year, with the annual reading at $187.0 million for FY2025, 5.71% down from the prior year.
  • Non-Current Assets for Q4 2025 was $187.0 million at ImmunityBio, down from $189.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $229.9 million in Q1 2023, with the low at $109.9 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $188.1 million, with a median of $199.9 million recorded in 2024.
  • The sharpest move saw Non-Current Assets surged 74.92% in 2022, then dropped 10.85% in 2024.
  • Over 5 years, Non-Current Assets stood at $134.6 million in 2021, then surged by 64.81% to $221.8 million in 2022, then dropped by 5.15% to $210.4 million in 2023, then fell by 5.71% to $198.3 million in 2024, then fell by 5.71% to $187.0 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $187.0 million, $189.5 million, and $193.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.